Search
2026
2025
2024
2023
-
Jun 26, 2026
YolTech to Present Interim Clinical Data of YOLT-203 at the 2026 OHF International Hyperoxaluria WorkshopRead More
-
May 29, 2026
YolTech Therapeutics Raises $70 Million in Series C FinancingRead More
-
May 14, 2026
YolTech Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation to YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)Read More
-
Mar 13, 2026
YolTech Therapeutics Receives FDA Clearance to Initiate Phase 2/3 Study of In Vivo Gene-Editing Therapy YOLT-202 in Alpha-1 Antitrypsin Deficiency (AATD)Read More
-
Mar 07, 2026
YolTech to Present at Keystone SymposiaRead More
